Ergänzende Stellungnahme der DOG, der RG und des BVA zur Therapie der proliferativen diabetischen Retinopathie^[*]

Im Jahr 2015 wurden in der Nationalen VersorgungsLeitlinie „Prävention und Therapie von Netzhautkomplikationen bei Diabetes“ unter anderem Kernaussagen zur Therapie der diabetischen Retinopathie konsentiert [1].

^* Diese Leitlinie erscheint auch in der Zeitschrift Der Ophthalmologe, Springer Verlag, Heidelberg.

Publication History

Article published online:
16 July 2020

• Literatur

• 1 Bundesärztekammer (BÄK); Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie (NVL) Prävention und Therapie von Netzhautkomplikationen bei Diabetes (2. Auflage, 2015). Im Internet (Stand: 17.12.2019): http://www.leitlinien.de/nvl/diabetes/netzhautkomplikationen
• 2 Gross JG, Glassman AR, Liu D. et al. Five-year outcomes of panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol 2018; 136: 1138-1148 doi:10.1001/jamaophthalmol.2018.3255
• 3 Lang GE, Stahl A, Voegeler J. et al. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy – the PRIDE study. Acta Ophthalmol 2019;
• 4 Sivaprasad S, Prevost AT, Bainbridge J. et al. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial. BMJ Open 2015; 5: e8405 doi:10.1136/bmjopen-2015-008405
• 5 Gupta MP, Kiss S, Chan RVP. Reversal of retinal vascular leakage and arrest of progressive retinal Nonperfusion with monthly anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy. Retina 2018; 38: e74-e75 doi:10.1097/IAE.0000000000002261
• 6 Wykoff CC, Nittala MG, Zhou B. et al. Intravitreal aflibercept for retinal nonperfusion in proliferative diabetic retinopathy: outcomes from the randomized RECOVERY trial. Ophthalmol Retina 2019; 3: 1076-1086 doi:10.1016/j.oret.2019.07.011
• 7 Ziemssen F, Roeck D, Marahrens L. et al. Bildgebung der diabetischen Retinopathie. Diabetologe 2018; 14: 557-567
• 8 Aiello LP, Odia I, Glassman AR. et al. Comparison of early treatment diabetic retinopathy study standard 7-field imaging with ultrawide-field imaging for determining severity of diabetic retinopathy. JAMA Ophthalmol 2019; 137: 65-73 doi:10.1001/jamaophthalmol.2018.4982
• 9 Nicholson L, Ramu J, Chan EW. et al. Retinal nonperfusion characteristics on ultra-widefield angiography in eyes with severe nonproliferative diabetic retinopathy and proliferative diabetic retinopathy. JAMA Ophthalmol 2019; 137: 626-631 doi:10.1001/jamaophthalmol.2019.0440
• 10 Ehlers JP, Jiang AC, Boss JD. et al. Quantitative ultra-widefield angiography and diabetic retinopathy severity: an assessment of panretinal leakage index, ischemic index and microaneurysm count. Ophthalmology 2019; 126: 1527-1532 doi:10.1016/j.ophtha.2019.05.034
• 11 Couturier A, Rey PA, Erginay A. et al. Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor. Ophthalmology 2019; 126: 1685-1694 doi:10.1016/j.ophtha.2019.06.022
• 12 Enders C, Baeurle F, Lang GE. et al. Visualization of retinal neovascularization with optical coherence tomography angiography in comparison with fluorescein angiography. Klin Monatsbl Augenheilkd 2019; 236: 1325-1330 doi:10.1055/a-0983-2271
• 13 Schwartz R, Khalid H, Sivaprasad S. et al. Objective evaluation of proliferative diabetic retinopathy using OCT. Ophthalmol Retina 2019;
• 14 Russell JF, Flynn HW, Sridhar J. et al. Distribution of diabetic neovascularization on ultra-widefield fluorescein angiography and on simulated widefield OCT angiography. Am J Ophthalmol 2019; 207: 110-120 doi:10.1016/j.ajo.2019.05.031
• 15 Russell JF, Shi Y, Hinkle JW. et al. Longitudinal wide-field swept-source OCT angiography of neovascularization in proliferative diabetic retinopathy after panretinal photocoagulation. Ophthalmol Retina 2019; 3: 350-361 doi:10.1016/j.oret.2018.11.008
• 16 Berufsverband der Augenärzte; Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie des diabetischen Makulaödems. Ophthalmologe 2019;
• 17 Klein R, Klein BE, Moss SE. et al. The Wisconsin epidemiologic study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107: 237-243
• 18 Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98 (5 Suppl.): 766-785
• 19 Zhou B, Mitchell TC, Rusakevich AM. et al. Noncompliance in prospective retina clinical trials: analysis of factors predicting loss to follow-up. Am J Ophthalmol 2019;
• 20 Sun JK, Glassman AR, Beaulieu WT. et al. Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy. Ophthalmology 2019; 126: 87-95
• 21 Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized trial. JAMA 2015; 314: 2137-2146 doi:10.1001/jama.2015.15217
• 22 Hutton DW, Stein JD, Glassman AR. et al. Five-year cost-effectiveness of intravitreous ranibizumab therapy vs. panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2019; 24: 1-9 doi:10.1001/jamaophthalmol.2019.4284
• 23 Obeid A, Gao X, Ali FS. et al. Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology 2018; 125: 1386-1392 doi:10.1016/j.ophtha.2018.02.034
• 24 Sun JK, Wang PW, Taylor S. et al. Durability of diabetic retinopathy improvement with as-needed ranibizumab: open-label extension of RIDE and RISE studies. Ophthalmology 2019; 126: 712-720 doi:10.1016/j.ophtha.2018.10.041
• 25 Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I. et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2014;